Study #2018-1031
A Phase III, Multicenter, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer (New Adjuvant TriAl with Ri
MD Anderson Study Status
Not Accepting
Treatment Agent
Ribociclib
Description
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer (EBC)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Early Breast Cancer
Study phase:
Phase III
Physician name:
Vicente Valero
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-898-4264
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.